IMV Inc IMVIF

What happened to this? Wasn't there a "deal"?

[Breakthorough1]

A. Hall to Thom Calandra, January 2022

"Merck is providing the drug and has been offered first right of refusal for providing the drug (pembro/Keytruda) for any follow-on studies that happen. The study is designed to be Stage 1 is, Does pembrolizumab plus (IMV’s) mavero equal better (results) than just pembro? And if it goes forward into Stage 2, the deal originally was that Merck would co-contribute to Stage 2 … so that as we push toward registration (of a commercial trial) Merck would be involved. So the first part of the study was ours to be funded; the second part is Merck’s to be funded. The reality was that it was more cost effective to close down the basket study … and the reason we are being a little coy with our press releases and we’re obviously still involved with Merck deeply and in conversations with Merck about how they want to fund the next step in bladder cancer and the next step in MSI-H (colon cancer, other tumors with high levels of micro-satellite instability. )"

[Sandinista]

Another misleading statement by Hall and approved by the board.  How these people dropped the ball and missed out on a global vaccine rush is incomprehensible. Total incompetence. Yet, they will all leave with their reputations intact and move on to the next opportunity to make even more money. No repercussions for a pathetically lousy job both by management and lack of oversight by board